TopoTarget partners its lead drug

Tuesday 2 February 2010

TopoTarget A/S, the Danish company focused on cancer treatments, has partnered its lead compound, belinostat, for $30 million upfront, potential fees of $320 million plus double digit royalties on sales.

 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark